Global Systemic Sclerosis (Scleroderma) Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
31 mai 2024 04h34 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Systemic Sclerosis (Scleroderma) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The...
Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type
16 mai 2024 10h45 HE
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Global Scleroderma Market Forecasts Promising Growth with Latest Industry Trends by 2027
30 janv. 2024 20h25 HE
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Scleroderma Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global scleroderma market is poised for...
Scleroderma Therapeutics Market is estimated to be US$ 4.3 Billion by 2032; Growing Incidence and Screening Rates of Scleroderma to Fuel-By PMI
18 sept. 2023 13h30 HE
|
PMI
Covina, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Scleroderma, also known as systemic sclerosis, is a rare and chronic autoimmune disease that primarily affects the connective tissues in the body. There...
Autoimmune Disease Testing Market is set to reach revenue of US$ 15.75 Billion, expected to grow at 10% CAGR during 2023 to 2033 period | Future Market Insights, Inc.
10 avr. 2023 03h55 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, April 10, 2023 (GLOBE NEWSWIRE) -- According to FMI estimations, the Autoimmune Disease Testing Market could increase from US$ 6.07 billion in 2023 to US$ 15.75 billion by 2033. The...
AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients
26 juil. 2022 17h50 HE
|
Aisa Pharma, Inc.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
30 mars 2022 08h00 HE
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
12 janv. 2022 07h30 HE
|
APIE Therapeutics
Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
14 août 2018 16h05 HE
|
aTyr Pharma, Inc.
SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference
26 juil. 2018 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...